4-Chloro-I(2)-[(methylamino)methyl]benzenepropanoic acid | 78590-19-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Chloro-I(2)-[(methylamino)methyl]benzenepropanoic acid
• 英文别名: 3-(4-chlorophenyl)-4-(methylamino)butanoic acid
• CAS: 78590-19-9
• 化学式: C₁₁H₁₄ClNO₂
• 分子量: 227.69
• InChiKey: BCWFBCYDMKBDGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• MEANS AND METHODS FOR SYNTHESIZING PRECURSORS OF Y-AMINOBUTYRIC ACID (GABA) ANALOGS
  申请人：RIJKSUNIVERSITEIT GRONINGEN

  公开号：EP3599246A1

  公开（公告）日：2020-01-29

  The invention relates to the fields of drug development and biocatalysis, more specifically to a biocatalytic route for asymmetric synthesis of precursors of y-aminobutyric acid (GABA) analogs. Provided is an isolated mutant 4-oxalocrototonate tautomerase (4-OT) enzyme comprising the following mutations (i) leucine at position 8 substituted with a tyrosine (L8Y) or a phenylalanine (L8F); (ii) methionine at position 45 substituted with a tyrosine (M45Y); and (iii) phenylalanine at position 50 substituted with an alanine (F50A), wherein the positions are numbered according to the amino acid sequence of 4-OT of Pseudomonas putida. Also provided is a method for the synthesis of a precursor for the pharmaceutically relevant enantiomer of a GABA analog, comprising (i) providing a y-nitroaldehyde using the 4-OT mutant enzyme, followed by (ii) subjecting the thus obtained y-nitroaldehyde to an enzymatic oxidation reaction catalyzed by an aldehyde dehydrogenase (EC 1.2.1.3).

  本发明涉及药物开发和生物催化领域，更具体地说，涉及一种不对称合成y-氨基丁酸（GABA）类似物前体的生物催化途径。本发明提供了一种分离的突变体 4-氧代丙酮酸同工酶（4-OT），该酶包含以下突变：(i) 第 8 位的亮氨酸被酪氨酸（L8Y）或苯丙氨酸（L8F）取代；(ii) 第 45 位的蛋氨酸被酪氨酸（M45Y）取代；(iii) 第 50 位的苯丙氨酸被丙氨酸（F50A）取代，其中各位置根据假单胞菌 4-OT 的氨基酸序列编号。还提供了一种合成 GABA 类似物的药用对映体的前体的方法，包括(i)使用 4-OT 突变体酶提供 y-硝基醛，然后(ii)将由此获得的 y-硝基醛置于醛脱氢酶（EC 1.2.1.3）催化的酶促氧化反应中。
• Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism
  申请人：Roberts Kathryn

  公开号：US20100029770A1

  公开（公告）日：2010-02-04

  Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.
• US8143311B2
  申请人：——

  公开号：US8143311B2

  公开（公告）日：2012-03-27